Aridis Pharmaceuticals (ARDS) Stock Price

Aridis Pharmaceuticals Price

NASDAQ·CLOSED
0.00
​
Market closed

Revenue has compounded at 31.3% per year over the past 7 years to 19.25 M USD. Aridis Pharmaceuticals's net margin stands at -159.7%, up from -801.8% several years earlier.

Aridis Pharmaceuticals stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aridis Pharmaceuticals business model & stock analysis

Aridis Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of immunotherapeutics and antibiotics for the treatment of infectious diseases. It was founded in 2003 in San Jose, California. The company's business model aims to address the gap in the infectious disease market caused by antibiotic resistance and the lack of new therapy options. Aridis has developed several patented technologies that allow for the quick and effective identification of potential candidates for new therapies. The company focuses on antibiotic development, utilizing a library of human monoclonal antibodies targeted specifically for infectious diseases. These antibodies can be used to target bacteria and achieve better efficacy against antibiotic resistance. Aridis has promising candidates in clinical development. The company also focuses on the development of immunotherapeutics for infectious diseases. They have developed a portfolio of monoclonal antibodies that target pathogenic microbes and can activate immune cells to strengthen the body's immune system. Some of Aridis' key products include Aerucin for the treatment of pneumonia and other respiratory diseases, and AR-101 for severe infections caused by Pseudomonas aeruginosa. Both products are currently in Phase II of development. Another important product is AR-301, a monoclonal antibody developed for the treatment of severe Staphylococcus infections. AR-301 has successfully completed Phase IIb studies and is currently undergoing accelerated approval by the US Food and Drug Administration (FDA). Aridis has formed collaborations with academic institutions and other biopharmaceutical companies to access the latest scientific knowledge and technologies. They have partnerships with multiple universities and research institutes worldwide. The company has also partnered with AmpliPhi Biosciences for the development of bacteriophage-based therapies for infectious diseases, and with Mount Sinai Health System for the development of immunotherapeutics for respiratory diseases. Overall, Aridis has a strong position in the infectious disease market and is well-positioned to address the gap caused by antibiotic resistance and the lack of new therapies. With a strong portfolio of patented technologies, promising candidates in clinical development, and broad partnerships, the company has the potential to become a leading player in the industry.

Frequently asked questions about Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc's business model revolves around the development and commercialization of innovative anti-infective therapies. The company focuses on utilizing its proprietary technology platforms to create monoclonal antibodies that can effectively target and neutralize infectious pathogens. By harnessing the power of the immune system, Aridis Pharmaceuticals aims to provide solutions for combating a wide range of infectious diseases, including bacterial, fungal, and viral infections. Through strategic partnerships and collaborations, the company aims to accelerate the development and commercialization of its product candidates, bringing much-needed therapeutic options to patients worldwide.

Aridis Pharmaceuticals Inc primarily operates in the biotechnology and pharmaceutical industries.

The main competitors of Aridis Pharmaceuticals Inc in the market include companies like Johnson & Johnson, Pfizer Inc, Moderna Inc, GlaxoSmithKline plc, and AstraZeneca plc.

Aridis Pharmaceuticals Inc, founded in 2003, is a biopharmaceutical company based in San Jose, California. Specializing in the discovery and development of targeted immunotherapies to treat infectious diseases, Aridis Pharmaceuticals has made significant advancements in combating severe infections. The company has a robust pipeline of novel therapies, utilizing its proprietary technologies such as Monoclonal Antibody AR-301, designed to neutralize bacterial toxins associated with severe pneumonia. Aridis Pharmaceuticals focuses on improving patient outcomes and reducing healthcare costs through the development of highly effective and safe immunotherapies. With a commitment to innovation, Aridis Pharmaceuticals is at the forefront of addressing unmet medical needs in the field of infectious diseases.

Aridis Pharmaceuticals Inc has achieved significant milestones in its development. The company successfully completed a Phase 1 clinical trial for its lead candidate, AR-301, a potential treatment for severe pneumonia caused by bacterial infections. Aridis also entered into a licensing agreement with Bharat Biotech to develop a vaccine for COVID-19. Furthermore, the company received a grant from the National Institutes of Health to support the development of AR-201, a potential treatment for hospital-acquired pneumonia. These achievements demonstrate Aridis Pharmaceuticals Inc's commitment to advancing innovative therapies for infectious diseases and its potential to make a significant impact in the healthcare industry.

Aridis Pharmaceuticals Inc primarily operates in the United States, focusing on the development and commercialization of innovative anti-infective therapies. With its headquarters in San Jose, California, the company leverages its proprietary technologies to address global infectious diseases. Aridis Pharmaceuticals Inc's presence extends beyond regional bounds, as it collaborates with international partners, conducts clinical trials, and explores potential expansion opportunities. Expanding its reach and impact, Aridis Pharmaceuticals Inc remains committed to delivering breakthrough treatments worldwide, combating infectious diseases and improving patient outcomes.

Aridis Pharmaceuticals Inc represents values of innovation, dedication, and commitment to improving global health. The company's corporate philosophy revolves around developing targeted and effective immunotherapies for infectious diseases. Aridis Pharmaceuticals Inc is focused on pioneering the development of novel monoclonal antibodies and antiviral therapeutics to combat various pathogens. With a strong emphasis on research and development, Aridis strives to bring groundbreaking treatments to market, addressing critical unmet medical needs. By leveraging advanced technologies and strategic collaborations, Aridis Pharmaceuticals Inc aims to make a positive impact on society by providing life-saving solutions for infectious diseases.

7 analysts currently rate the Aridis Pharmaceuticals stock: 6 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Aridis Pharmaceuticals share trades at 0.00 EUR (0.00 USD).

The Aridis Pharmaceuticals share (ARDS) is listed on 1 stock exchanges, including: NASDAQ (ARDS).

Aridis Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of infectious diseases. The company's business model is based on several areas, including research and development, production, and distribution. Aridis focuses on the discovery and development of novel immunotherapies, particularly monoclonal antibodies and immunomodulators that specifically target the underlying pathomechanisms of infectious diseases. The company has an extensive pipeline of product candidates targeting various bacterial and viral infections. Aridis also places importance on quality and efficient processes in its production facilities. The company collaborates closely with leading pharmaceutical companies and distribution partners for international marketing and distribution. In addition to infectious diseases, Aridis aims to expand its technology and expertise in immunology to other areas such as cancer immunotherapies and autoimmune diseases. The company works with academic institutions and government agencies to enhance its research efforts and accelerate the development of novel immunotherapies. Overall, Aridis' business model is based on the development and commercialization of innovative immunotherapies for infectious diseases, with a strong focus on research and development, efficient production, and collaborations with partners.

The revenue cannot currently be calculated for Aridis Pharmaceuticals.

The profit cannot currently be calculated for Aridis Pharmaceuticals.

The P/E ratio cannot be calculated for Aridis Pharmaceuticals at the moment.

The P/S cannot be calculated for Aridis Pharmaceuticals currently.

The Eulerpool Quality Score for Aridis Pharmaceuticals is 5/10.

The ISIN of Aridis Pharmaceuticals is US0403341045. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Aridis Pharmaceuticals is A2N38H. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Aridis Pharmaceuticals is ARDS. The ticker symbol is used to trade Aridis Pharmaceuticals shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
770,000.00 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Aug 14, 2018
ISIN
US0403341045
Cusip
040334104
Sedol
BD49J40
Market capitalization
1,877.73 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2023
—
P/Ee 2024
—
P/Ee 2025
0.00
P/Ee 2026
0.00
P/Ee 2027
0.00
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
169.87 %
Last updated Nov 19, 2026, 3:53 AM

Aridis Pharmaceuticals Ticker

NASDAQ · ARDS

Aridis Pharmaceuticals FIGI

ARDS:US · BBG005TNS1Z5ARDS:PQ · BBG00LGF35H9ARDS:UV · BBG00LGF35J7